SWShuai Wang

Shuai Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shuai Wang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Peng Wang

    Department of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University

    5 shared publications
  • Tianmeng Li

    Department of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University

    5 shared publications
  • Jun Liu

    Department of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University

    4 shared publications
  • Li Gu

    Department of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University

    4 shared publications
  • Ming Wei

    Department of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University

    3 shared publications
  • Ming Wei

    Department of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

    2 shared publications

Latest Publications

  • Open Access

    Essential fatty acids disrupt the mycolic acid-rich cell envelope of clinical Nocardia isolates: a membrane-targeting approach to combat persistent infections

    by Ming Wei, Shiwang Xie, Peng Wang, Tianmeng Li, Jun Liu, Jingxian Yang, Xinmin Xu, Dan Luo, Li Gu, Shuai Wang

    Background: Conventional antibiotics against slow-growing, mycolic acid-rich Nocardia often require prolonged therapy and are associated with high relapse rates. Membrane-targeting essential fatty acids may circumvent growth-dependent resistance. Methods: Five essential fatty acids were screened against 82 clinical Nocardia isolates by broth microdilution. Docosahexaenoic acid (DHA) was further assessed for bactericidal kinetics, membrane integrity by propidium iodide staining and scanning electron microscopy, transcriptomic profiling, and combined activity with amikacin and tobramycin. Results: α-Linolenic acid, γ-linolenic acid, eicosapentaenoic acid and DHA exhibited comparable activity (MIC 50/ MIC 90 : 31.25/62.50 μM), corresponding to mass concentration ranges of 8.7 to 10.3 μg/mL for MIC 50 and 17.4 to 20.6 μg/mL for MIC 90 . However, arachidonic acid was markedly less active. DHA rapidly disrupted the Nocardia cell envelope, causing propidium iodide influx and ultrastructural damage, and achieved concentration-dependent bactericidal killing within 1 h, a feat not observed with imipenem. Transcriptomic analysis of the surviving subpopulation revealed downregulation of the proton-pumping Nuo complex, upregulation of type II NADH dehydrogenase (Ndh), and global induction of translation machinery. These transcriptional changes, together with pre-existing membrane damage, additively enhanced the activity of amikacin against intrinsically resistant N. wallacei (FICI, 0.51-0.56). Conclusions: These findings demonstrate that DHA displays rapid membrane-disruptive activity and can enhance amikacin activity against Nocardia under the defined in vitro conditions.

  • Open Access

    Clinical and Epidemiologic Characteristics of Anaerobic Bacteria Originating from Blood Cultures: A Five-Year Retrospective Study

    by Yaqin Peng, Jiamin Qin, Lu Bai, Lihong Bai, Xiaowen Jiang, Huiting Li, Kang Liao, Shuai Wang, Penghao Guo

    Background: With the rise of anaerobic bacteremia and resistance to anaerobes for commonly used agents, the resistance patterns of many anaerobes have changed significantly among different geographic areas and medical facilities. This study investigated the clinical and epidemiologic characteristics of anaerobic bacteremia for therapeutic optimization at the local level. Methods: This retrospective observational study included all positive blood cultures (BC) from 2020 to 2024. For patients with anaerobic bacteria originating from BCs, clinical and microbiological data were collected. Results: In total, 239 anaerobic strains were isolated from 223 patients. Among BC-positive bacteria, the proportion of anaerobes accounted for 4.4% (239/5450), with a gradual increase from 3.0% in 2020 to 6.1% in 2024. The most common anaerobes were Bacteroides fragilis (34.7%) and Cutibacterium acnes (20.5%). The resistance rates of gram-negative anaerobes to penicillin, imipenem, and meropenem were 94.4%, 21.1%, and 35.2%, respectively, which were much higher than those of gram-positive anaerobes (16.7%, 0%, 0%). Among the 223 cases, abdominal disorders were the most frequent underlying condition (54.7%). In the empirical antibiotic therapy, 94.6% of the patients received β-lactam antibiotics, and the infection symptoms improved in 74.9% of the patients. For Bacteroides spp. bacteremia, the improvement rate in patients treated with carbapenems and β-lactam/β-lactamase inhibitor combinations was 78.1% and 40.0%, respectively. Conclusion: The study presents valuable data for monitoring and improving anaerobic bacteremia treatment in Southern of China.

  • Open Access

    Clinical profiling, antifungal drug susceptibility, and biofilm formation ability in pulmonary mucormycosis

    by Peng Wang, Yaqin Peng, Jun Liu, Tianmeng Li, Dan Zhang, Li Gu, Qiangyi Wang, Mingze Su, Ming Wei, Shuai Wang

    Pulmonary mucormycosis (PM), a life-threatening infection caused by Mucorales, exhibits high mortality. Comprehensive data integrating clinical profiling, antifungal susceptibility, and biofilm formation ability are limited. This retrospective study characterized 26 adult PM patients at a Beijing tertiary-care hospital. Data on demographics, underlying diseases, co-infections, and outcomes were collected. Clinical Mucorales isolates underwent molecular identification via 18 S rRNA gene sequencing and phylogenetic analysis. In vitro susceptibility against nine antifungals (amphotericin B, fluconazole, voriconazole, itraconazole, posaconazole, caspofungin, micafungin, anidulafungin, 5-flucytosine) was determined using Sensititre YeastOne YO10 panels. Biofilm biomass was assessed (24 h, 48 h, 72 h) via the crystal violet staining assay. Patients were predominantly older males (median age 66 years, 65.4% male) with high comorbidity burden (92.3%). All-cause in-hospital mortality was 38.5%. Strikingly, 80.8% had co-infections. Temporal analysis revealed that viral (77.8%) and fungal (62.5%) co-infections often preceded the detection of Mucorales. Molecular identification confirmed Rhizopus spp. (54%) predominated, followed by Rhizomucor spp. (19%), Mucor spp. (19%), and Lichtheimia spp. (8%). Antifungal testing showed amphotericin B possessed the most consistent activity (MIC50/MIC90: 1/2 µg/mL). Posaconazole was the most potent azole (MIC50/MIC90: 0.25/1 µg/mL), but profound genus-level heterogeneity was observed. Biofilm assessment at the 48-h peak revealed biofilm formation in 84.6% (22/26) of isolates. This study highlights the high prevalence of antecedent viral/fungal co-infections preceding Mucorales detection and significant mortality, despite in vitro susceptibility to amphotericin B/posaconazol. In addition, most of the strains demonstrated biofilm formation ability, with evident genus-level heterogeneity. These findings emphasize the imperative of species-level identification and consideration of genus-specific traits to guide effective management of this life-threatening infection.


  • Open Access

    Transcriptome analysis reveals the molecular mechanism of γ-linolenic acid eradicating the biofilm of vancomycin-resistant Enterococcus faecium

    by Ming Wei, Peng Wang, Tianmeng Li, Jun Liu, Yu Wang, Li Gu, Shuai Wang

    Introduction: Vancomycin-resistant Enterococcus faecium (VRE-fm) biofilms pose a significant clinical challenge due to the limited effectiveness of traditional antibiotics. This study investigates the potential of γ-linolenic acid (GLA) as a novel antibiofilm agent.Methods: Transcriptome analysis was performed on the V27 isolate, comparing cells in mature biofilms treated with and without GLA. The findings were further validated using qRT-PCR on six VRE-fm isolates and two E. faecalis isolates.Results: Transcriptome analysis revealed a significant downregulation in the expression levels of genes associated with biofilm formation, including fruA, fruB, sgrA, lpxtg-cwa, tfpp, lafA, lafB, malP, fsrA, and fsrC’, while a significant upregulation was observed in the expression of fsrBD. Validation by qRT-PCR in six VRE-fm isolates confirmed the significant changes in the expression levels of all genes except for lpxtg-cwa, with statistical significance. The expression of bgsB and bgsA genes, which are the homologs of lafA and lafB genes, along with the Fsr-regulated genes gelE and sprE in E. faecalis, were also found to be downregulated by GLA. In addition, KEGG analysis identified specific metabolic pathways that were significantly downregulated by GLA.Conclusion: GLA effectively targets multiple aspects of biofilm formation in VRE-fm, including the downregulation of key biofilm-related genes, the inhibition of quorum sensing systems, and the modulation of metabolic pathways. GLA emerges as a promising candidate for eradicating Enterococcus biofilms.

  • Open Access

    Antimicrobial and antibiofilm effects of essential fatty acids against clinically isolated vancomycin-resistant Enterococcus faecium

    by Ming Wei, Peng Wang, Tianmeng Li, Qiangyi Wang, Mingze Su, Li Gu, Shuai Wang

    Introduction: Enterococcus faecium is a leading cause of hospital-acquired infections, which has become a serious public health concern. The increasing incidence of vancomycin-resistant E. faecium (VRE-fm) raises an urgent need to find new antimicrobial agents as a complement to traditional antibiotics. The study aimed to evaluate the antimicrobial and antibiofilm activity of essential fatty acids (EFAs) against VRE-fm, and further explore the molecular mechanism of the antibiofilm activity of EFAs.Method: The microdilution broth method was used for antimicrobial susceptibility testing with traditional antibiotics and EFAs, including α-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), linoleic acid (LOA), γ-linolenic acid (GLA), and arachidonic acid (AA). The effect of EFAs on cell morphology of VRE-fm was investigated by scanning electron microscopy. The crystal violet method was used to evaluate the antibiofilm activities of EFAs against VRE-fm. Furthermore, the expression of biofilm-related genes (acm, atlA, esp, and sagA) of VRE-fm isolates under the action of GLA was analyzed using quantitative reverse transcription PCR (qRT-PCR) assay.Results: VRE-fm isolates were highly resistant to most traditional antibiotics, only highly susceptible to quinupristin-dalfopristin (90.0%), tigecycline (100%), and linezolid (100%). EPA, DHA, and GLA exhibited excellent antimicrobial activity. The MIC50/90 of EPA, DHA, and GLA were 0.5/1, 0.25/0.5, and 0.5/1 mM, respectively. SEM imaging showed that strain V27 adsorbed a large number of DHA molecules. Furthermore, all EFAs exhibited excellent inhibition and eradication activities against VRE-fm biofilms. The biofilm inhibition rates of EFAs ranged from 45.3% to 58.0%, and eradication rates ranged from 54.1% to 63.4%, against 6 VRE-fm isolates with moderate biofilm formation ability. GLA exhibited remarkable antibiofilm activity against VRE-fm isolates. The qRT-PCR analysis showed that GLA could significantly down-regulate the expression of the atlA gene (P < 0.01) of VRE-fm.Conclusion: DHA showed the strongest antibacterial activity, while GLA showed the strongest antibiofilm effect among the EFAs with antibacterial activity. Our novel findings indicate that the antibiofilm activity of GLA may be through down-regulating the atlA gene expression in VRE-fm. Therefore, DHA and GLA had the potential to be developed as therapeutic agents to treat infections related to multiple antimicrobial-resistant E. faecium.


  • Open Access

    12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial

    by Bingfeng Han, Wu Liu, Juan Du, Hanyu Liu, Tianshuo Zhao, Shubo Yang, Shuai Wang, Sihui Zhang, Bei Liu, Yaqiong Liu, et al.

    Background: In initial studies, the immunogenicity and safety of hepatitis B vaccines in patients with diabetes has been assessed in China. Methods: In six township health centers in Gansu Province, 232 diabetic patients and 77 healthy people were allocated to receive two 3-dose hepatitis B vaccines (Group D20SC 0-1-6; Group D20CHO 0-1-6; Group ND20SC 0-1-6). Participants were followed up at 12 months after being fully vaccinated. One dose of the vaccine was randomly administered to non-responders. Chi-square test was used to compare the differences in response rate between two groups. Results: The anti-HBs response rates of three groups decreased from 84.1%, 89.1% and 88.3% at one month to 64.6%, 79.8% and 71.4% at twelve months. There was no statistical difference in the immune response rates between Group D20SC 0-1-6 and Group ND20SC 0-1-6; however, that of Group D20CHO 0-1-6 was higher than that of Group D20SC 0-1-6. After revaccination, the geometric mean concentrations were 491.7 mIU/mL and 29.7 mIU/mL after using vaccines containing 60 μg and 20 μg HBsAg. Conclusions: At 12 months, immune response in diabetic patients were not significantly different from that in healthy people. Revaccination with one dose of hepatitis B vaccine containing 60 μg HBsAg for non-responders was more satisfactory.